- Home
- CAN vs TNGX Comparison
CAN vs TNGX Comparison
Compare CAN & TNGX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CAN
- TNGX
- Stock Information
- Founded
- CAN 2013
- TNGX 2014
- Country
- CAN Singapore
- TNGX United States
- Employees
- CAN N/A
- TNGX N/A
- Industry
- CAN Semiconductors
- TNGX Biotechnology: Pharmaceutical Preparations
- Sector
- CAN Technology
- TNGX Health Care
- Exchange
- CAN Nasdaq
- TNGX Nasdaq
- Market Cap
- CAN 425.9M
- TNGX 413.6M
- IPO Year
- CAN 2019
- TNGX N/A
- Fundamental
- Price
- CAN $2.01
- TNGX $2.85
- Analyst Decision
- CAN Strong Buy
- TNGX Strong Buy
- Analyst Count
- CAN 3
- TNGX 8
- Target Price
- CAN $3.00
- TNGX $13.14
- AVG Volume (30 Days)
- CAN 16.7M
- TNGX 1.2M
- Earning Date
- CAN 02-25-2025
- TNGX 11-06-2024
- Dividend Yield
- CAN N/A
- TNGX N/A
- EPS Growth
- CAN N/A
- TNGX N/A
- EPS
- CAN N/A
- TNGX N/A
- Revenue
- CAN $229,630,000.00
- TNGX $43,383,000.00
- Revenue This Year
- CAN $24.51
- TNGX $27.73
- Revenue Next Year
- CAN $84.90
- TNGX N/A
- P/E Ratio
- CAN N/A
- TNGX N/A
- Revenue Growth
- CAN N/A
- TNGX 15.67
- 52 Week Low
- CAN $0.72
- TNGX $2.59
- 52 Week High
- CAN $3.27
- TNGX $13.01
- Technical
- Relative Strength Index (RSI)
- CAN 47.20
- TNGX 41.79
- Support Level
- CAN $1.84
- TNGX $2.60
- Resistance Level
- CAN $1.97
- TNGX $3.65
- Average True Range (ATR)
- CAN 0.19
- TNGX 0.25
- MACD
- CAN -0.05
- TNGX 0.01
- Stochastic Oscillator
- CAN 40.26
- TNGX 24.88
About CAN Canaan Inc.
Canaan Inc is a developer of supercomputing chips and the manufacturer of digital blockchain computing equipment as well as the supplier of the overall scheme for computer software and hardware of digital blockchain. The revenues of the company are derived from the sales of Bitcoin mining machines and related parts.
About TNGX Tango Therapeutics Inc.
Tango Therapeutics Inc is a biotechnology company. It is dedicated towards discovering novel drug targets and delivering the next generation of precision medicine for the treatment of cancer. It is engaged in the business of discovering and developing precision oncology therapies. Its program TNG908, is an MTA-cooperative inhibitor of PRMT5 designed to work selectively in cancer cells with an MTAP deletion. Its pipeline further consists of discovery programs such as, TNG462, TNG348, TNG260 and others for multiple cancer types with limited treatment options.